(REGN) Regeneron Pharmaceuticals - Ratings and Ratios
Eylea, Dupixent, Libtayo, Praluent, Kevzara
REGN EPS (Earnings per Share)
REGN Revenue
Description: REGN Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a U.S.-based biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines across multiple therapeutic areas, including ophthalmology, immunology, oncology, cardiovascular, metabolic, infectious, and rare diseases.
Its flagship products generate the bulk of revenue: EYLEA (wet age-related macular degeneration and diabetic eye disease) delivered $2.0 billion in 2023 sales; Dupixent (atopic dermatitis and asthma) posted $2.5 billion; and Libtayo (cutaneous squamous-cell carcinoma) contributed $2.1 billion. Additional marketed therapies include Praluent, REGEN-COV, Kevzara, Inmazeb, ARCALYST, ZALTRAP, Evkeeza, Ordspono, and Veopoz, with a pipeline targeting eye, inflammatory, cardiovascular, metabolic, infectious, oncology, pain, and hematologic indications.
The company maintains a strong balance sheet, reporting approximately $5.5 billion of cash and marketable securities at year-end 2023, and it reinvested roughly $2.3 billion in R&D, reflecting its commitment to pipeline expansion. Key sector drivers-an aging global population increasing demand for ophthalmic and cardiovascular therapies, and sustained biotech R&D tax incentives in the United States-support Regeneron’s growth outlook.
Strategic collaborations extend Regeneron’s capabilities: a partnership with Mammoth Biosciences to develop in-vivo CRISPR-based gene-editing therapies, and an alliance with Sonoma Biotherapeutics to advance engineered regulatory T-cell treatments, both aimed at diversifying its product portfolio beyond conventional biologics.
For a deeper, data-driven valuation framework, you might explore the detailed analyst models available on ValueRay.
REGN Stock Overview
| Market Cap in USD | 60,325m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1991-04-02 |
REGN Stock Ratings
| Growth Rating | -39.0% |
| Fundamental | 79.4% |
| Dividend Rating | 13.6% |
| Return 12m vs S&P 500 | -48.4% |
| Analyst Rating | 4.28 of 5 |
REGN Dividends
| Dividend Yield 12m | 0.46% |
| Yield on Cost 5y | 0.46% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | 5.8% |
REGN Growth Ratios
| Growth Correlation 3m | 38.2% |
| Growth Correlation 12m | -80.1% |
| Growth Correlation 5y | 44.9% |
| CAGR 5y | -8.08% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.14 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.44 |
| Sharpe Ratio 12m | -0.65 |
| Alpha | -49.74 |
| Beta | 0.307 |
| Volatility | 33.67% |
| Current Volume | 651.6k |
| Average Volume 20d | 1010.6k |
| Stop Loss | 555.3 (-4.1%) |
| Signal | 0.26 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (4.46b TTM) > 0 and > 6% of Revenue (6% = 852.9m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 1.17pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 92.81% (prev 115.4%; Δ -22.64pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 4.74b > Net Income 4.46b (YES >=105%, WARN >=100%) |
| Net Debt (709.3m) to EBITDA (5.42b) ratio: 0.13 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (108.6m) change vs 12m ago -5.89% (target <= -2.0% for YES) |
| Gross Margin 81.98% (prev 82.80%; Δ -0.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.26% (prev 37.38%; Δ 0.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 134.2 (EBITDA TTM 5.42b / Interest Expense TTM 36.6m) >= 6 (WARN >= 3) |
Altman Z'' 10.30
| (A) 0.35 = (Total Current Assets 16.86b - Total Current Liabilities 3.67b) / Total Assets 38.22b |
| (B) 0.88 = Retained Earnings (Balance) 33.68b / Total Assets 38.22b |
| warn (B) unusual magnitude: 0.88 — check mapping/units |
| (C) 0.13 = EBIT TTM 4.91b / Avg Total Assets 37.15b |
| (D) 4.07 = Book Value of Equity 33.73b / Total Liabilities 8.28b |
| Total Rating: 10.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.39
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 6.92% = 3.46 |
| 3. FCF Margin 27.05% = 6.76 |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda 0.13 = 2.49 |
| 6. ROIC - WACC (= 7.44)% = 9.31 |
| 7. RoE 15.11% = 1.26 |
| 8. Rev. Trend 53.36% = 4.00 |
| 9. EPS Trend -47.73% = -2.39 |
What is the price of REGN shares?
Over the past week, the price has changed by +1.18%, over one month by -2.74%, over three months by +6.36% and over the past year by -39.93%.
Is Regeneron Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of REGN is around 480.83 USD . This means that REGN is currently overvalued and has a potential downside of -17%.
Is REGN a buy, sell or hold?
- Strong Buy: 14
- Buy: 5
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the REGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 725.1 | 25.2% |
| Analysts Target Price | 725.1 | 25.2% |
| ValueRay Target Price | 528.2 | -8.8% |
Last update: 2025-10-18 05:04
REGN Fundamental Data Overview
P/E Trailing = 14.3476
P/E Forward = 15.456
P/S = 4.244
P/B = 2.1241
P/EG = 1.154
Beta = 0.307
Revenue TTM = 14.21b USD
EBIT TTM = 4.91b USD
EBITDA TTM = 5.42b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 709.3m USD (from netDebt column, last quarter)
Enterprise Value = 55.56b USD (60.32b + Debt 2.71b - CCE 7.47b)
Interest Coverage Ratio = 134.2 (Ebit TTM 4.91b / Interest Expense TTM 36.6m)
FCF Yield = 6.92% (FCF TTM 3.84b / Enterprise Value 55.56b)
FCF Margin = 27.05% (FCF TTM 3.84b / Revenue TTM 14.21b)
Net Margin = 31.37% (Net Income TTM 4.46b / Revenue TTM 14.21b)
Gross Margin = 81.98% ((Revenue TTM 14.21b - Cost of Revenue TTM 2.56b) / Revenue TTM)
Gross Margin QoQ = 81.90% (prev 80.48%)
Tobins Q-Ratio = 1.45 (Enterprise Value 55.56b / Total Assets 38.22b)
Interest Expense / Debt = 0.13% (Interest Expense 3.60m / Debt 2.71b)
Taxrate = 8.37% (127.1m / 1.52b)
NOPAT = 4.50b (EBIT 4.91b * (1 - 8.37%))
Current Ratio = 4.60 (Total Current Assets 16.86b / Total Current Liabilities 3.67b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 29.94b)
Debt / EBITDA = 0.13 (Net Debt 709.3m / EBITDA 5.42b)
Debt / FCF = 0.18 (Net Debt 709.3m / FCF TTM 3.84b)
Total Stockholder Equity = 29.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.67% (Net Income 4.46b / Total Assets 38.22b)
RoE = 15.11% (Net Income TTM 4.46b / Total Stockholder Equity 29.50b)
RoCE = 15.60% (EBIT 4.91b / Capital Employed (Equity 29.50b + L.T.Debt 1.99b))
RoIC = 14.29% (NOPAT 4.50b / Invested Capital 31.49b)
WACC = 6.85% (E(60.32b)/V(63.03b) * Re(7.15%) + D(2.71b)/V(63.03b) * Rd(0.13%) * (1-Tc(0.08)))
Discount Rate = 7.15% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -81.65 | Cagr: -2.31%
[DCF Debug] Terminal Value 75.66% ; FCFE base≈3.59b ; Y1≈3.05b ; Y5≈2.33b
Fair Price DCF = 410.0 (DCF Value 42.71b / Shares Outstanding 104.2m; 5y FCF grow -18.28% → 3.0% )
EPS Correlation: -47.73 | EPS CAGR: -59.30% | SUE: -4.0 | # QB: 0
Revenue Correlation: 53.36 | Revenue CAGR: 8.51% | SUE: 2.88 | # QB: 1
Additional Sources for REGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle